Royalty Pharma buys Zealand Pharma rusfertide economics in USD 100 million deal
RPRX•Royalty Pharma acquires rusfertide economics from Zealand Pharma
Royalty Pharma agreed to provide USD 100 million to Zealand Pharma for its economics tied to rusfertide.
The deal transfers rights to a 1% royalty on potential global net sales, plus regulatory and commercial milestones.
The payment will be split into USD 50 million at closing and USD 50 million due on the first anniversary.
Zealand keeps a 0.25% royalty on annual net global sales above USD 1.5 billion; Royalty Pharma holds 0.75% above that level.
The FDA has set a PDUFA goal date for the rusfertide NDA in Q3 2026; Takeda is responsible for global commercialization.
